Consumption Patterns and In Vitro Resistance of Streptococcus pneumoniae to Fluoroquinolones

Simoens, Steven; Verhaegen, Jan; Bleyenbergh, Pascal Van; Peetermans, Willy; Decramer, Marc

doi:10.1128/aac.00019-11

Cited by 13 publications

(6 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moxifloxacin had low MIC 90 values against these three CARTIs pathogens irrespective of resistance to ␤-lactams and macrolides. This is consistent with other reports from North America, Japan and Europe [31][32][33][34]. Results from the CARTIPS study have confirmed some significant regional differences in the antimicrobial susceptibilities of S. pneumoniae, MSSA, K. pneumoniae, H. influenzae, Streptococcus spp.…”

Section: Discussionsupporting

confidence: 92%

Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009–2010

Wang

Chen

et al. 2011

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 92%

Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009–2010

Wang

Chen

et al. 2011

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

“…Moxifloxacin and solithromycin may thus offer an advantage over the other molecules within their pharmacological class since both molecules are less prone to select resistance than others in their respective class (31,69). Moreover, moxifloxacin MICs have remained stable over the last 10 years, despite extensive usage (70,71), and preclinical studies show that solithromycin is barely affected by mechanisms conferring resistance to other macrolides (31,72).…”

Section: Discussionmentioning

confidence: 99%

Antibiotic Activity against Naive and Induced Streptococcus pneumoniae Biofilms in an In Vitro Pharmacodynamic Model

Vandevelde

Tulkens

2014

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Biofilms play a role in the pathogenicity of pneumococcal infections. A pharmacodynamic in vitro model of biofilm was developed that allows characterization of the activity of antibiotics against viability and biomass by using in parallel capsulated (ATCC 49619) and noncapsulated (R6) reference strains. Naive biofilms were obtained by incubating fresh planktonic cultures for 2 to 11 days in 96-well polystyrene plates. Induced biofilms were obtained using planktonic bacteria collected from the supernatant of 6-day-old naive biofilms. Biomass production was more rapid and intense in the induced model, but the levels were similar for both strains. Full concentration responses fitting sigmoidal regressions allowed calculation of maximal efficacies and relative potencies of drugs. All antibiotics tested (amoxicillin, clarithromycin, solithromycin, levofloxacin, and moxifloxacin) were more effective against young naive biofilms than against old or induced biofilms, except macrolides/ketolides, which were as effective at reducing viability in 2-day-old naive biofilms and in 11-day-old induced biofilms of R6. Macrolides/ketolides, however, were less potent than fluoroquinolones against R6 (approximately 5-to 20-fold-higher concentrations needed to reduction viability of 20%). However, at concentrations obtainable in epithelial lining fluid, the viabilities of mature or induced biofilms were reduced 15 to 45% (amoxicillin), 17 to 44% (macrolides/ketolides), and 12 to 64% (fluoroquinolones), and biomasses were reduced 5 to 45% (amoxicillin), 5 to 60% (macrolides/ketolides), and 10 to 76% (fluoroquinolones), with solithromycin and moxifloxacin being the most effective and the most potent agents (due to lower MICs) in their respective classes. This study allowed the ranking of antibiotics with respect to their potential effectiveness in biofilm-related infections, underlining the need to search for still more effective options.

show abstract

“…Fluoroquinolone (FQ) resistance at present is a less significant problem in the treatment of RTIs caused by S. pneumoniae [21][22][23], but resistant strains may emerge in immunocompromised patients [24], patients with structural lung disease and those with previous antibiotic exposure [25].…”

Section: S Pneumoniaementioning

confidence: 99%

Antibiotic stewardship challenges in the management of community-acquired infections for prevention of escalating antibiotic resistance

Garau

Nicolau

Wullt

et al. 2014

Journal of Global Antimicrobial Resistance

View full text Add to dashboard Cite

Community-acquired infections, including respiratory tract infections (RTIs) and urinary tract infections (UTIs), represent a major burden for most healthcare systems, partially due to ineffective or inappropriate antibiotic treatment leading to clinical failure, which often requires alternative antibiotics for cure. Appropriate antimicrobial use not only maximises clinical success in the treatment of community-acquired infections, but also minimises unintended consequences such as resistance development or collateral damage. This article outlines a range of antibiotic stewardship strategies and other preventative approaches that support the management of community-acquired infections, based on existing antibiotic use for community-acquired infections and the current resistance patterns among common RTI and UTI pathogens.

show abstract

Consumption Patterns and In Vitro Resistance of Streptococcus pneumoniae to Fluoroquinolones

Cited by 13 publications

References 3 publications

Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009–2010

Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009–2010

Antibiotic Activity against Naive and Induced Streptococcus pneumoniae Biofilms in an In Vitro Pharmacodynamic Model

Antibiotic stewardship challenges in the management of community-acquired infections for prevention of escalating antibiotic resistance

Contact Info

Product

Resources

About